Sentinext Therapeutics Sdn. Bhd. develops vaccines and therapeutics for tropical infectious diseases. Its pharmaceutical research and development focuses on EV71, polio, influenza and dengue diseases. The company was founded by Mary Jane Cardosa and Peter Samuel Wulff in 2009 and is headquartered in Penang, Malaysia.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Serum Institute of India Pvt. Ltd. is the vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 140 countries across the globe in their national immunization programs, saving millions of lives throughout the world.

BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. British Technology Group International that began operation in 1948 became BTG in March 1995. Its headquarters is in London in the United Kingdom.

Biocell Laboratories is a medical company that provides diagnostics, custom labeling, centrifugation, formulation and purification services.

Jiangsu Kanion Pharma is a pharmaceuticals company based out of LIANYUNGANG. Jiangsu Kanion Pharma representatives, don’t miss out on opportunities to build relationships with members on LinkedIn. Claim your page, write a simple description, and share content to attract followers that can lead to new customers, brand fans, and future employees.

Temasek Life Sciences Laboratory (TLL) was established in August 2002 and as a Singapore Non Profit Philanthropic Research Organisation focusing primarily on understanding the cellular mechanisms that underlie the development and physiology of plants, fungi and animals which provides foundation for biotechnology innovation.

Takeda Vaccines, Inc., a subsidiary of Takeda Pharmaceutical Co., Ltd., is an American company located in Bozeman, MT. The firm provides biological research and development services.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Biota Scientific Management Pty Ltd., a subsidiary of Vaxart, Inc., is an Australian company located in Notting Hill that develops anti-infective drugs.

LSI Medience Corp. engages in the clinical examination business. It also engages in the diagnostic agent and drug discovery support business. The company was founded on April 1, 2014 and is headquartered in Tokyo, Japan.

Plasbio is a technology company that developes aritifical intelligence collaborative robot-based animal study automation devices.

GENOMICA SAU provides genetic identification and molecular diagnostic services. Its services include paternity tests, fornsic genetics technological transfers and laboratory genetic identification for criminal investigation. The firm also offers various diagnostic kits and reagents such as CLART PneumoVir, CLINICAL ARRAYS Metabona and CLINICAL ARRAYS-Papillomavirus. It also provides laboratory installation and technical support services and training courses for laboratory, clinical and forensics professionals. The company was founded in 1990 and is headquartered in Madrid, Spain.

Institute of Laboratory Animal Science, a subsidiary of University of Zurich, is a Swiss company located in Schlieren that provides research, services and teaching in translational and basic research.

The Carlos III Health Institute (Spanish: Instituto de Salud Carlos III; ISCIII) is a Spanish public health research institute, legally constituted as a public research agency (Spanish: Organismo Público de Investigación), a type of quasi-autonomous entity under Spanish law. The agency is integrated in the Department of Science and Innovation, although it also reports to the Department of Health in the institute's activities relating health, healthcare and its planning.

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), of which the EV71 vaccine is currently in Phase III clinical trials, pneumococcal conjugate, pneumococcal polysaccharides, and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines.

Guangdong Yuewei Edible Mushroom Technology Co., Ltd., established on 1998-11-16, The scope of business includes the cultivation of edible fungi;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Cosmetics Retail;Cosmetics Wholesale;software development;software sales;Aquatic product retail;Wholesale of aquatic products;General merchandise sales;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of daily chemical products;Chemical product sales(No licensed chemical products);Primary processing of edible agricultural products;Retailing of Edible Agricultural Products;Feed Raw Material Sales;Feed Additive Sales;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Personal Hygiene Sales;Sales of hygiene products and single-use medical products;Health Consulting Services(Does not include medical services);Science popularization service;Production of edible fungi;Edible fungi management;Import and export of edible fungi;Cosmetic production;feed production;Health food production;Health food sales;Sales of formula food for special medical purposes;Import and export;Technology Import and Export;food production;food business;food business(Selling prepackaged food);beverage production;Production of tea products;pharmaceutical production;Drug Wholesale;Drug retail

Yunnan Yunhe Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include medicines, raw material medicines, Chinese and western medicine preparations, beverages, and health products. The company was founded in 1958 and is headquartered in Honghe, China.

Shanghai WuXi AppTec New Drug Development Co., Ltd., established on 2002-04-02, Business scope includes new drugs,R&D of pharmaceutical intermediates,In-region synthesis of pharmaceutical small molecule compounds and compound libraries,Manufacture of fine chemical products,processing,Chemical Products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals)promotion of,Industrial Investment,Engaged in the import and export of goods and technology,Drug Wholesale,engaged in detection technology,Biological Technology,computer technology,Technology development in the field of data technology specialization,technology transfer,technical consulting,Technical Services,Mechanical equipment and spare parts,Health Advisory,medical consultation,Self-owned real estate development and operation,Quality inspection technical service,Exhibition business service. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]